Bevacizumab and glioblastoma: scientific review, newly reported updates, and ongoing controversies.
about
The Role of a Single Angiogenesis Inhibitor in the Treatment of Recurrent Glioblastoma Multiforme: A Meta-Analysis and Systematic ReviewEpidermal growth factor, latrophilin, and seven transmembrane domain-containing protein 1 marker, a novel angiogenesis markerVascular heterogeneity and targeting: the role of YKL-40 in glioblastoma vascularizationA randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastomaImmunotherapeutic advancements for glioblastoma.Use of bevacizumab in recurrent glioblastoma.Bevacizumab for the treatment of cervical cancer.Bevacizumab in recurrent glioblastoma: open issues.Effect of Bevacizumab Plus Temozolomide-Radiotherapy for Newly Diagnosed Glioblastoma with Different MGMT Methylation Status: A Meta-Analysis of Clinical Trials.A validated microRNA profile with predictive potential in glioblastoma patients treated with bevacizumab.The Long and Winding Road: From the High-Affinity Choline Uptake Site to Clinical Trials for Malignant Brain Tumors.Bevacizumab combined with chemotherapy for glioblastoma: a meta-analysis of randomized controlled trials.3D Mathematical Modeling of Glioblastoma Suggests That Transdifferentiated Vascular Endothelial Cells Mediate Resistance to Current Standard-of-Care Therapy.Evolutionary basis of a new gene- and immune-therapeutic approach for the treatment of malignant brain tumors: from mice to clinical trials for glioma patients.Overall survival in patients with glioblastoma before and after bevacizumab approval.Health-related quality of life outcomes from CABARET: a randomized phase 2 trial of carboplatin and bevacizumab in recurrent glioblastoma.Glioblastoma stem cell differentiation into endothelial cells evidenced through live-cell imaging.Re-irradiation strategies in combination with bevacizumab for recurrent malignant glioma.Differential Expression and Clinical Significance of Transforming Growth Factor-Beta Isoforms in GBM Tumors.Effectiveness of lomustine and bevacizumab in progressive glioblastoma: a meta-analysis.
P2860
Q26752321-6EA96F5B-A141-46B5-ADF7-2003BA965B07Q26771513-B849EF94-96E0-413C-9E74-DB9B4B31C559Q26781833-D68352DD-9350-43DE-8901-644077003998Q37253358-094253EE-E2A0-40B1-8A29-B40BFB746D4FQ38358124-EECC019E-FB74-436B-8B12-C41813FC6C83Q38438668-BED60895-A422-49FD-9DCA-2C2811C107EDQ38706483-192653C5-D7D0-46B8-B926-22D8DCAF5D77Q38965301-56ECBC32-9B92-4468-81E9-F190246E047BQ39339970-15C8564E-0849-4DCB-85CC-999081C6CB37Q39616746-1F015C9F-D874-49B3-B5EE-47F7ADFF17E7Q41189810-3FB115C6-062C-4B13-A29F-C59C1E35CD97Q41342037-C28D0814-802E-43FC-B3AA-7691FBFE3273Q46025187-E4DE526E-2E47-4F6C-8125-64EF2812EE7AQ47318878-1D36A4CF-8A17-4904-A8FB-B3BE07E3B8F5Q47809684-92DFC878-B447-4D79-BBC2-44F466C3D091Q48113265-5BAE41AE-5036-4113-A5CE-7D7C749BD993Q48246862-CDF0577A-18DD-4449-92D2-F6613844254EQ48528266-8C1DAFFC-EC4F-4FA2-A6E0-2C9BC0C2DEC7Q52593655-E095A28D-6EBA-4A34-BDEB-CBAE45ECA192Q55386847-05974D77-3AD0-4E46-BED9-9B92E1ED5E3C
P2860
Bevacizumab and glioblastoma: scientific review, newly reported updates, and ongoing controversies.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Bevacizumab and glioblastoma: ...... es, and ongoing controversies.
@en
type
label
Bevacizumab and glioblastoma: ...... es, and ongoing controversies.
@en
prefLabel
Bevacizumab and glioblastoma: ...... es, and ongoing controversies.
@en
P2093
P2860
P356
P1433
P1476
Bevacizumab and glioblastoma: ...... es, and ongoing controversies.
@en
P2093
Justin T Jordan
Kathryn M Field
Mark A Rosenthal
Patrick Y Wen
P2860
P304
P356
10.1002/CNCR.28935
P407
P577
2014-09-26T00:00:00Z